A Covid-19 vaccine that has been developed by an American biotechnology company has been found to be safe and able to stimulate an immune response in the humans against the virus, its manufacturer, Moderna, announced on Monday.
In the phase one clinical trial, eight patients who received the vaccine at the lowest and middle doses developed neutralising antibodies to the virus.
Meanwhile, Kenyan researcher Dr F. George Njoroge and his team of scientists at Merck Pharmaceutical Company have said that a drug approved by the US Food and Drug Administration for treatment of hepatitis C has now demonstrated good potency in inhibiting Covid-19 proliferation in cells.
Dr Njoroge said the drug, boceprevir, had a strong binding to the enzyme that Covid-19 uses to process its proteins.
Dr Njoroge said he was excited to undertake further studies on the drug.
